These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 19351753)
1. G3139, an anti-Bcl-2 antisense oligomer that binds heparin-binding growth factors and collagen I, alters in vitro endothelial cell growth and tubular morphogenesis. Stein CA; Wu S; Voskresenskiy AM; Zhou JF; Shin J; Miller P; Souleimanian N; Benimetskaya L Clin Cancer Res; 2009 Apr; 15(8):2797-807. PubMed ID: 19351753 [TBL] [Abstract][Full Text] [Related]
2. Comparison of d-g3139 and its enantiomer L-g3139 in melanoma cells demonstrates minimal in vitro but dramatic in vivo chiral dependency. Lai JC; Brown BD; Voskresenskiy AM; Vonhoff S; Klussman S; Tan W; Colombini M; Weeratna R; Miller P; Benimetskaya L; Stein CA Mol Ther; 2007 Feb; 15(2):270-8. PubMed ID: 17235304 [TBL] [Abstract][Full Text] [Related]
3. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab. Loomis R; Carbone R; Reiss M; Lacy J Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752 [TBL] [Abstract][Full Text] [Related]
4. Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro. Benimetskaya L; Ayyanar K; Kornblum N; Castanotto D; Rossi J; Wu S; Lai J; Brown BD; Popova N; Miller P; McMicken H; Chen Y; Stein CA Clin Cancer Res; 2006 Aug; 12(16):4940-8. PubMed ID: 16914583 [TBL] [Abstract][Full Text] [Related]
5. G3139 induces cell death by caspase-dependent and -independent apoptosis on human melanoma cell lines. Nakamura S; Inui M; Kamei T; Nakase M; Okumura K; Tagawa T Oncol Rep; 2006 Jun; 15(6):1563-8. PubMed ID: 16685396 [TBL] [Abstract][Full Text] [Related]
6. Gene profiling study of G3139- and Bcl-2-targeting siRNAs identifies a unique G3139 molecular signature. Anderson EM; Miller P; Ilsley D; Marshall W; Khvorova A; Stein CA; Benimetskaya L Cancer Gene Ther; 2006 Apr; 13(4):406-14. PubMed ID: 16195754 [TBL] [Abstract][Full Text] [Related]
7. Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells. Benimetskaya L; Lai JC; Khvorova A; Wu S; Hua E; Miller P; Zhang LM; Stein CA Clin Cancer Res; 2004 Dec; 10(24):8371-9. PubMed ID: 15623615 [TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis by G3139 in melanoma cells. Benimetskaya L; Lai JC; Khvorova A; Wu S; Miller P; Stein CA Ann N Y Acad Sci; 2005 Nov; 1058():235-45. PubMed ID: 16394140 [TBL] [Abstract][Full Text] [Related]
9. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft. Spugnini EP; Biroccio A; De Mori R; Scarsella M; D'Angelo C; Baldi A; Leonetti C J Transl Med; 2011 Jul; 9():125. PubMed ID: 21798045 [TBL] [Abstract][Full Text] [Related]
10. Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells. Lefèvre G; Babchia N; Calipel A; Mouriaux F; Faussat AM; Mrzyk S; Mascarelli F Invest Ophthalmol Vis Sci; 2009 Mar; 50(3):1047-57. PubMed ID: 19029025 [TBL] [Abstract][Full Text] [Related]
11. G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner. Lai JC; Benimetskaya L; Santella RM; Wang Q; Miller PS; Stein CA Mol Cancer Ther; 2003 Oct; 2(10):1031-43. PubMed ID: 14578468 [TBL] [Abstract][Full Text] [Related]
12. Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen). Raffo A; Lai JC; Stein CA; Miller P; Scaringe S; Khvorova A; Benimetskaya L Clin Cancer Res; 2004 May; 10(9):3195-206. PubMed ID: 15131061 [TBL] [Abstract][Full Text] [Related]
13. Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells. Lai JC; Benimetskaya L; Khvorova A; Wu S; Hua E; Miller P; Stein CA Mol Cancer Ther; 2005 Feb; 4(2):305-15. PubMed ID: 15713901 [TBL] [Abstract][Full Text] [Related]
14. Angiogenesis alteration by defibrotide: implications for its mechanism of action in severe hepatic veno-occlusive disease. Benimetskaya L; Wu S; Voskresenskiy AM; Echart C; Zhou JF; Shin J; Iacobelli M; Richardson P; Ayyanar K; Stein CA Blood; 2008 Nov; 112(10):4343-52. PubMed ID: 18711003 [TBL] [Abstract][Full Text] [Related]
15. Heterodimerization of FGF-receptor 1 and PDGF-receptor-alpha: a novel mechanism underlying the inhibitory effect of PDGF-BB on FGF-2 in human cells. Faraone D; Aguzzi MS; Ragone G; Russo K; Capogrossi MC; Facchiano A Blood; 2006 Mar; 107(5):1896-902. PubMed ID: 16322476 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. Benimetskaya L; Miller P; Benimetsky S; Maciaszek A; Guga P; Beaucage SL; Wilk A; Grajkowski A; Halperin AL; Stein CA Mol Pharmacol; 2001 Dec; 60(6):1296-307. PubMed ID: 11723237 [TBL] [Abstract][Full Text] [Related]
17. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia. Dai G; Chan KK; Liu S; Hoyt D; Whitman S; Klisovic M; Shen T; Caligiuri MA; Byrd J; Grever M; Marcucci G Clin Cancer Res; 2005 Apr; 11(8):2998-3008. PubMed ID: 15837754 [TBL] [Abstract][Full Text] [Related]
18. Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in vitro and in vivo. Ma Y; Zhao W; Li Y; Pan Y; Wang S; Zhu Y; Kong L; Guan Z; Wang J; Zhang L; Yang Z Biomaterials; 2019 Mar; 197():182-193. PubMed ID: 30660994 [TBL] [Abstract][Full Text] [Related]
19. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654 [TBL] [Abstract][Full Text] [Related]
20. Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice. Lopes de Menezes DE; Hu Y; Mayer LD J Exp Ther Oncol; 2003; 3(2):72-82. PubMed ID: 12822513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]